San Diego, CA Clinical Trials Report — July 2026

San Diego participants should act now if they are considering a study scheduled to close soon: 27 recruiting trials are expected to close within the next 90 days, including 4 that accept healthy volunteers. San Diego currently has 710 recruiting trials across 335 research facilities, giving patients and volunteers a wide range of local options while enrollment remains open.

July added 16 new trials, slightly below 18 in June and 17 in May. New openings cover obesity, post-traumatic stress disorders, chronic lymphocytic leukemia, chronic rhinitis, heart failure, diabetic foot ulcers, intensive-care delirium, and immunization against human metapneumovirus.

Closing windows for local participants

People affected by the following conditions should contact study teams promptly. A projected closing date can change if a trial reaches its enrollment target early:

• Atopic dermatitis (3 trials)
• Cancer (2 trials)
• Breast cancer screening (1 trial)
• Double-expressor lymphoma (1 trial)
• Colorectal cancer (1 trial)
• Cystic fibrosis (1 trial)
• Diabetic foot ulcer (1 trial)
• Vascular dementia (1 trial)
• Breast carcinoma in situ (1 trial)
• Grief (1 trial)

Four closing-soon studies accept healthy volunteers. Across San Diego, 87 healthy-volunteer trials are currently recruiting, and 3 of July’s 16 new trials accept healthy participants. Volunteers should check age requirements, medication restrictions, screening procedures, and the number of visits before applying.

Major new opportunities in obesity, vaccines, and kidney disease

San Diego’s new-trial mix includes 5 behavioral studies, 4 device studies, and 3 drug studies, along with diagnostic, biological, dietary-supplement, and other research. Several openings stand out because of their phase, size, sponsor, or local academic involvement:

• NCT07684235 is Amgen’s Phase 3 MARITIME-1-EXTENSION study of maridebart cafraglutide in adults with obesity or overweight. The extension study plans to enroll 3,200 participants and evaluates long-term efficacy, safety, and tolerability.
• NCT07734649 is Sanofi’s Phase 1/2 study of an RSV and human metapneumovirus vaccine candidate in adults aged 60 and older. The multicenter trial plans to enroll 2,400 participants and evaluates immune response and safety.
• NCT07693543, sponsored by the University of California, San Diego, is a Phase 2 study testing nicotinamide riboside supplementation in adults with moderate chronic kidney disease. The study plans to include 30 participants.
• NCT07730268 is the Vivio At-Home Study, sponsored by Ventric Health, LLC. It evaluates whether the Vivio System can track heart-failure status and compares its measurements with CardioMEMS measurements in a study planning 500 participants.
• NCT07736729 is the SMART-BMI study of continuous wearable biometric monitoring during obesity treatment. The study plans to enroll 260 adults who are undergoing weight-loss surgery or starting weight-loss medication, using a smart ring to track health signals.
• NCT07711327 examines atrial fibrillation among people with hematologic malignancies who are beginning Bruton’s tyrosine kinase inhibitor therapy. The study plans to follow 500 participants.

Obesity and post-traumatic stress disorders each account for 2 new trials. Other new conditions appear once each, including chronic lymphocytic leukemia, chronic rhinitis, critical illness, delirium in the intensive care unit, diabetic foot ulcer, heart failure, and human metapneumovirus immunization.

San Diego’s leading research locations

The University of California San Diego system and Rady Children’s Hospital account for the largest concentrations of local studies. These facilities offer access to research in areas including cancer, pediatrics, heart disease, neurological conditions, infectious diseases, metabolic health, and behavioral health.

• University of California San Diego (37 trials)
• University of California, San Diego (36 trials)
• Rady Children’s Hospital - San Diego (31 trials)
• Rady Children’s Hospital (30 trials)
• UC San Diego Medical Center - Hillcrest (25 trials)
• Research Site (23 trials)
• Kaiser Permanente-San Diego Zion (21 trials)
• VA San Diego Healthcare System, San Diego, CA (20 trials)
• San Diego State University (15 trials)
• Rady Children’s Hospital San Diego (14 trials)
• Naval Medical Center San Diego (9 trials)
• Scripps Health (9 trials)

Some facility names appear separately in trial listings even when they are part of the same broader health system. Participants should search across the UC San Diego and Rady Children’s listings, as well as nearby Kaiser Permanente, VA, Scripps, and Naval Medical Center sites, to avoid missing eligible studies.

Who can participate this month?

Of the 16 new trials, none include children, one is female-only, and none are male-only. 14 include older adults, making age-appropriate vaccine and chronic-disease studies particularly relevant to seniors. The VA Office of Research and Development sponsors 4 new trials, while the University of California, San Diego sponsors 2. Sanofi, DexCom, Scripps Health, and other sponsors also appear in the July pipeline.

The sponsor mix includes 6 studies categorized as other, 5 industry-sponsored studies, 4 federally sponsored studies, and 1 network study. Healthy volunteers, adults with obesity or heart failure, older adults, and people with cancer or chronic kidney disease may find relevant options, but each study requires separate eligibility screening.

Other California cities to consider

Participants able to travel can also search nearby California research markets. Los Angeles has 25 trials, San Francisco 22, Palo Alto and Duarte 10 each, La Jolla and Sacramento 8 each, and Anaheim and Stanford 7 each. La Jolla is especially close to San Diego and may provide additional access alongside the city’s university and hospital sites.

San Diego’s new-trial count has moved from 23 in February to 15 in March, 12 in April, 17 in May, 18 in June, and 16 in July. With 87 healthy-volunteer opportunities and multiple studies approaching their enrollment deadlines, checking local listings early will remain the best way to find a suitable opening as the summer research pipeline develops.